Evidence map›Paper›PMID 32201620›Full record

ArticleBMJ global health2020

The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study.

Katharine Jane Looker, Christine Johnston, Nicky J Welton, Charlotte James, Peter Vickerman, Katherine M E Turner, Marie-Claude Boily, Sami L Gottlieb

Open access · goldAbstract read
In one paragraph

Article in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 5 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 5 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Katharine Jane LookerPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-3375-0807
Christine JohnstonDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Nicky J WeltonPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Charlotte JamesPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Peter VickermanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Katherine M E TurnerBristol Veterinary School, University of Bristol, Bristol, UK.
Marie-Claude BoilyDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.
Sami L GottliebDepartment of Reproductive Health and Research, World Health Organization, Geneve, Switzerland.
University of Bristol · GBAt Bristol · GBImperial College London · GBUniversity of Washington · USWorld Health Organization - Pakistan · PK

Funding

Enhanced collaboration between US NIH and WHO on biomedical researchU01AI108543 · NIAID · WORLD HEALTH ORGANIZATION · PI TROEDSSON, HANS · 2013 to 2018
$3.7M
Medical Research Council MR/R015600/1NIAID NIH HHS U01 AI108543World Health Organization 001
6 · The paper itself

Abstract

Introduction: Herpes simplex virus (HSV) infection can cause painful, recurrent genital ulcer disease (GUD), which can have a substantial impact on sexual and reproductive health. HSV-related GUD is most often due to HSV type 2 (HSV-2), but may also be due to genital HSV type 1 (HSV-1), which has less frequent recurrent episodes than HSV-2. The global burden of GUD has never been quantified. Here we present the first global and regional estimates of GUD due to HSV-1 and HSV-2 among women and men aged 15-49 years old. Methods: We developed a natural history model reflecting the clinical course of GUD following HSV-2 and genital HSV-1 infection, informed by a literature search for data on model parameters. We considered both diagnosed and undiagnosed symptomatic infection. This model was then applied to existing infection estimates and population sizes for 2016. A sensitivity analysis was carried out varying the assumptions made. Results: We estimated that 187 million people aged 15-49 years had at least one episode of HSV-related GUD globally in 2016: 5.0% of the world's population. Of these, 178 million (95% of those with HSV-related GUD) had HSV-2 compared with 9 million (5%) with HSV-1. GUD burden was highest in Africa, and approximately double in women compared with men. Altogether there were an estimated 8 billion person-days spent with HSV-related GUD globally in 2016, with 99% of days due to HSV-2. Taking into account parameter uncertainty, the percentage with at least one episode of HSV-related GUD ranged from 3.2% to 7.9% (120-296 million). However, the estimates were sensitive to the model assumptions. Conclusion: Our study represents a first attempt to quantify the global burden of HSV-related GUD, which is large. New interventions such as HSV vaccines, antivirals or microbicides have the potential to improve the quality of life of millions of people worldwide.

Indexed as

Global HealthHerpes GenitalisUlcerAdolescentAdultFemaleHerpesvirus 1, HumanHerpesvirus 2, HumanHumansMaleMiddle AgedModels, BiologicalYoung Adultepidemiologyinfections, diseases, disorders, injuries

Identifiers

PMID32201620
PMCPMC7061890
OpenAlexW3011206473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.